Digital human twins represent computationally integrated avatars of patient physiology that can predict patient response to compounds, improving patient outcomes, minimizing side effects, and continuously monitoring and adjust treatments.

17 December 2025 Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds. Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer li

24 September 2025 Berkeley-based Prellis Biologics, Inc., developer of human in vitro antibody generation platform, announces collaboration with Eli Lilly to accelerate the discovery of human antibodies for multiple disease targets. Prellis’ EXIS™ lymph node platform for target‑specific human antibody generation is a shining example of ingenuity by which several technologies were combined to capture human-relevant physiology. The traditional method of antibody generatio

25 September 2025 Cedars-Sinai Medical Center based in Los Angeles has been awarded $5M by Advanced Research Projects Agency for Health (ARPA-H) to develop a human-based AI-driven KronosRx platform for improved prediction of adverse drug effects. The ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program aims to revolutionize preclinical drug safety prediction by facilitating the development of next gen in vitro and in silico model

12 June 2025 Cambridge, Massachusetts-based Parallel Bio announces it has raised $21 million Series A funding to scale up and automate the production of its immune organoid in vitro platform. This funding round led by AIX Ventures was supported by prominent leaders in AI and biotech, including Marc Benioff, founder and CEO of Salesforce. Beyond infections and autoimmune diseases, it is widely recognized that the human immune systems plays a key role in a great number of c

27 October 2025 As we enter a new era of drug discovery, where IND authorization can now be granted based on human data only, marking a clean departure from mandatory animal testing, Qureator's human organ-on-chip platform has laid the groundwork for the world’s first IND approval of its kind. The IND grant concerns SillaJen's BAL0891-tislelizumab combination therapy to treat solid tumors. Qureator's patient-derived vascularized tumor immune microenvironment (TME) model h

26 September 2025 Inductive Bio, an AI drug discovery partner developing virtual chemistry labs, is awarded up to $21M by Advanced Research Projects Agency for Health (ARPA-H) to develop AI-powered human-relevant drug toxicity prediction models. ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program aims to revolutionize preclinical drug safety prediction by leveraging human-based models that assess safety of drug candidates more re